AWM Investment Company Inc. Makes New $10.61 Million Investment in Palvella Therapeutics, Inc. $PVLA

Key Points

• AWM Investment Company acquired 69,416 Palvella Therapeutics shares worth approximately $10.61 million, representing a 0.48% stake. Institutional investors collectively own 40.11% of PVLA.
• Analyst sentiment is broadly positive, with a consensus “Buy” rating and an average price target of $209.14; individual targets include $207 to $270.
• PVLA shares recently traded at $148.24, near their 52-week high, but the company reported a quarterly loss of $1.52 per share—worse than the $1.17 analyst consensus.

AWM Investment Company Inc. acquired a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 69,416 shares of the company's stock, valued at approximately $10,608,000. AWM Investment Company Inc. owned 0.48% of Palvella Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of Palvella Therapeutics during the 1st quarter valued at $7,553,000. Goldman Sachs Group Inc. acquired a new stake in shares of Palvella Therapeutics in the first quarter valued at $533,000. Geode Capital Management LLC boosted its stake in Palvella Therapeutics by 84.7% during the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company's stock valued at $3,923,000 after buying an additional 79,787 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock valued at $73,000 after buying an additional 3,242 shares in the last quarter. Finally, Rhumbline Advisers acquired a new position in Palvella Therapeutics during the second quarter worth about $224,000. Institutional investors own 40.11% of the company's stock.

Analysts Set New Price Targets

PVLA has been the subject of a number of research analyst reports. Chardan Capital raised shares of Palvella Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. HC Wainwright reaffirmed a "buy" rating and issued a $270.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Stephens reissued an "overweight" rating and set a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $209.14.

Palvella Therapeutics Trading Up 1.7%

Shares of NASDAQ:PVLA opened at $148.24 on Wednesday. The stock has a market capitalization of $2.14 billion, a PE ratio of -30.69 and a beta of -0.17. Palvella Therapeutics, Inc. has a 1 year low of $49.81 and a 1 year high of $161.38. The firm has a fifty day moving average price of $143.70 and a 200 day moving average price of $125.71.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, sell-side analysts forecast that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the sale, the chief operating officer directly owned 2,154 shares in the company, valued at $327,860.34. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by corporate insiders.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source